Nasdaq:US$17.92 (-0.64) | HKEX:HK$28.60 (-0.75) | AIM:£2.79 (-0.11)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors